187 related articles for article (PubMed ID: 12231518)
1. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Hidalgo M; Aylesworth C; Hammond LA; Britten CD; Weiss G; Stephenson J; Schwartz G; Patnaik A; Smith L; Molpus K; Felton S; Gupta E; Ferrante KJ; Tortora A; Sonnichsen DS; Skillings J; Rowinsky EK
J Clin Oncol; 2001 May; 19(9):2493-503. PubMed ID: 11331328
[TBL] [Abstract][Full Text] [Related]
5. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Kurata T; Shimada Y; Tamura T; Yamamoto N; Hyodo I; Saeki T; Takashima S; Fujiwara K; Wakasugi H; Kashimura M
J Clin Oncol; 2000 Sep; 18(17):3164-71. PubMed ID: 10963645
[TBL] [Abstract][Full Text] [Related]
7. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.
Gelmon KA; Latreille J; Tolcher A; Génier L; Fisher B; Forand D; D'Aloisio S; Vernillet L; Daigneault L; Lebecq A; Besenval M; Eisenhauer E
J Clin Oncol; 2000 Dec; 18(24):4098-108. PubMed ID: 11118471
[TBL] [Abstract][Full Text] [Related]
9. Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
Sessa C; Perotti A; Salvatorelli E; Minotti G; Viganò L; Lladò A; Capri G; Locatelli A; Colombini S; Peccatori F; Voi M; Marsoni S; Gianni L
Eur J Cancer; 2004 Mar; 40(4):563-70. PubMed ID: 14962724
[TBL] [Abstract][Full Text] [Related]
10. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
Kouroussis C; Kakolyris S; Mavroudis D; Androulakis N; Kalbakis K; Agelaki S; Sarra E; Souglakos J; Christodoulakis M; Samonis G; Georgoulias V
Am J Clin Oncol; 2001 Aug; 24(4):404-7. PubMed ID: 11474274
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Ando M; Yonemori K; Katsumata N; Shimizu C; Hirata T; Yamamoto H; Hashimoto K; Yunokawa M; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2012 Feb; 69(2):457-65. PubMed ID: 21853310
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
Shi M; Sun J; Zhou J; Yu H; Yu S; Xia G; Wang L; Teng Y; Liu G; Yu C; Feng J; Shen Y
Invest New Drugs; 2018 Apr; 36(2):269-277. PubMed ID: 28868573
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Kurzrock R; Gabrail N; Chandhasin C; Moulder S; Smith C; Brenner A; Sankhala K; Mita A; Elian K; Bouchard D; Sarantopoulos J
Mol Cancer Ther; 2012 Feb; 11(2):308-16. PubMed ID: 22203732
[TBL] [Abstract][Full Text] [Related]
15. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
